Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001306946 | SCV001496334 | likely benign | Duchenne muscular dystrophy | 2025-01-14 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002437047 | SCV002751651 | uncertain significance | Cardiovascular phenotype | 2022-06-24 | criteria provided, single submitter | clinical testing | The p.Q926K variant (also known as c.2776C>A), located in coding exon 21 of the DMD gene, results from a C to A substitution at nucleotide position 2776. The glutamine at codon 926 is replaced by lysine, an amino acid with similar properties. Based on data from gnomAD, the A allele has an overall frequency of 0.002% (4/182706) total alleles studied, with 1 hemizygote(s) observed. The highest observed frequency was 0.04% (3/7473) of Ashkenazi Jewish alleles. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001830234 | SCV002089675 | uncertain significance | Becker muscular dystrophy; Duchenne muscular dystrophy; Cardiomyopathy; Dystrophin deficiency | 2019-07-29 | no assertion criteria provided | clinical testing |